Hype check
16:8 fasting met its best test — and lost
5 min read ·
Skipping breakfast is free, simple, and wrapped in more longevity narrative than any supplement. That makes the TREAT trial's result one of the most practically useful in this field — and one of the least advertised.
What TREAT did
TREAT randomised adults with overweight or obesity to 16:8 time-restricted eating or three structured meals a day, with weight as the primary outcome. After twelve weeks, the fasting group had lost no more weight than the control group. The trial also flagged a signal worth taking seriously: an exploratory finding of greater lean-mass loss in the fasting group.
What this does and does not settle
One twelve-week trial does not close a field. Longer trials, other fasting schedules, and metabolic endpoints beyond weight remain live questions — the calorie-restriction literature that motivates fasting research, including the CALERIE trial, is genuinely interesting. What TREAT does settle is the specific, most-sold claim: that restricting your eating window causes weight loss by itself, no other change required. Tested directly, it did not.
The honest fasting pitch that survives is unexciting: it is one way to eat less, it suits some people, and if it costs you muscle it may be the wrong way for older adults in particular.